The future development of personalized medicine depends on a vast exchange of data from
different sources, as well as harmonized integrative analysis of large-scale clinical health …

Chronic kidney disease presents a health challenge that has a complex underlying
pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options …

The physiologically based pharmacokinetic modeling (PBPK) approach can predict drug
pharmacokinetics (PK) by combining changes in blood flow and pathophysiological …

Background and Objectives P-glycoprotein (P-gp) is one of the most intensely studied
transporters owing to its broad tissue distribution and substrate specificity. Existing research …

Over the last several decades, angiotensin-converting enzyme inhibitors (ACEIs) have been
a staple in the treatment of hypertension and renovascular disorders in children. One of the …

In the past decade, only a small number of papers have elaborated on the application of
physiologically based pharmacokinetic (PBPK) modeling across different areas. In this …

Piperine has been reported to inhibit the enzyme activity of cytochrome P450 (CYP) 3A4.
The aim of this study was to develop and validate a physiologically based pharmacokinetic …

Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-
tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or …

In vitro methods are widely used in modern toxicological testing; however, the data cannot
be directly employed for risk assessment. In vivo toxicity of chemicals can be predicted from …

The evolution in the development of drugs has increased the popularity of physiologically
based pharmacokinetic (PBPK) models. This study seeks to assess the PK of metoprolol in …